https://ift.tt/eA8V8J
Swiss biotech firm Relief Therapeutics has seen its share price climb by nearly 38,000% so far this year, as it develops a drug focused on respiratory failure arising from severe Covid-19.
Monday, December 14, 2020
A Swiss biotech firm developing a Covid treatment has seen its share price soar 38,000% this year
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment